Serial Micro-CT Assessment of the Therapeutic Effects of Rosiglitazone in a Bleomycin-Induced Lung Fibrosis Mouse Model.
10.3348/kjr.2014.15.4.448
- Author:
Eun Jung CHOI
1
;
Gong Yong JIN
;
Se Mi BOK
;
Young Min HAN
;
Young Sun LEE
;
Myung Ja JUNG
;
Keun Sang KWON
Author Information
1. Department of Radiology, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Institute for Medical Sciences, Jeonju 561-712, Korea. gyjin@chonbuk.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Microcomputed tomography;
Bleomycin;
Fibrosis;
Rosiglitazone;
Lung
- MeSH:
Animals;
Bleomycin;
Disease Models, Animal;
Female;
Mice;
Mice, Inbred C57BL;
Observer Variation;
Pulmonary Fibrosis/chemically induced/*drug therapy/*radiography;
Thiazolidinediones/*therapeutic use;
*X-Ray Microtomography
- From:Korean Journal of Radiology
2014;15(4):448-455
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of this study was to assess the therapeutic effects of rosiglitazone with serial micro-CT findings before and after rosiglitazone administration in a lung fibrosis mouse model induced with bleomycin. MATERIALS AND METHODS: We instilled the bleomycin solution directly into the trachea in twenty mice (female, C57BL/6 mice). After the instillation with bleomycin, mice were closely observed for 3 weeks and then all mice were scanned using micro-CT without sacrifice. At 3 weeks, the mice were treated with rosiglitazone on days 21 to 27 if they had abnormal CT findings (n = 9, 45%). For the mice treated with rosiglitazone, we performed micro-CT with mouse sacrifice 2 weeks after the rosiglitazone treatment completion. We assessed the abnormal CT findings (ground glass attenuation, consolidation, bronchiectasis, reticular opacity, and honeycombing) using a five-point scale at 3 and 6 weeks using Wilcoxon-signed ranked test. The micro-CT findings were correlated with the histopathologic results. RESULTS: One out of nine (11.1%) mice improved completely. In terms of consolidation, all mice (100%) showed marked decrease from 3.1 +/- 1.4 at 3 weeks to 0.9 +/- 0.9 at 6 weeks (p = 0.006). At 6 weeks, mild bronchiectasis (n = 6, 66.7%), mild reticular opacity (n = 7, 77.8%) and mild honeycomb patterns (n = 3, 33.3%) appeared. CONCLUSION: A serial micro-CT enables the evaluation of drug effects in a lung fibrosis mouse model.
